LYEL Earnings Lyell Immunopharma, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q1 2026 | 2026-03-31 | -1.10 | 2026-05-06 | 10-Q |
| FY 2025 | 2025-12-31 | -16.06 | 2026-03-12 | 10-K |
| Q3 2025 | 2025-09-30 | -8.38 | 2025-11-12 | 10-Q |
| Q2 2025 | 2025-06-30 | -6.42 | 2025-08-12 | 10-Q |
| Q1 2026 | 2025-03-31 | -3.54 | 2026-05-06 | 10-Q |
| FY 2025 | 2024-12-31 | -26.23 | 2026-03-12 | 10-K |
| Q3 2025 | 2024-09-30 | -11.83 | 2025-11-12 | 10-Q |
| Q2 2025 | 2024-06-30 | -8.36 | 2025-08-12 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.24 | 2025-05-13 | 10-Q |
| FY 2025 | 2023-12-31 | -18.70 | 2026-03-12 | 10-K |
| Q3 2024 | 2023-09-30 | -0.73 | 2024-11-07 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.52 | 2024-08-07 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.27 | 2024-05-06 | 10-Q |
| FY 2024 | 2022-12-31 | -0.74 | 2025-03-11 | 10-K |
| Q3 2023 | 2022-09-30 | -0.71 | 2023-11-07 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.43 | 2023-08-08 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.28 | 2023-05-04 | 10-Q |
| FY 2023 | 2021-12-31 | -1.84 | 2024-02-28 | 10-K |
| Q3 2022 | 2021-09-30 | -1.66 | 2022-11-08 | 10-Q |
| Q2 2022 | 2021-06-30 | -3.91 | 2022-08-04 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.